Vincent D. Marshall

Vincent D. Marshall

Auto-generated profile, based on publicly available information

Vincent D. Marshall

University of Michigan College of Pharmacy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
HIHuda Ismail
Huda Ismail
VMVincent D. Marshall
Vincent D. Marshall
MPMinal Patel
Minal Patel
MTMadiha Tariq
Madiha Tariq
RMRima A. Mohammad
Rima A. Mohammad

1 June 2018 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
KAKayla Ambroziak
Kayla Ambroziak
NINour Ibrahim
Nour Ibrahim
VMVincent D. Marshall
Vincent D. Marshall
SKSarah E. Kelling
Sarah E. Kelling

27 February 2020 in Transplant International
Verified
Journal Article
Closed access
PDF file
ABAlexandra L. Bixby
Alexandra L. Bixby
SSSuhail A Shaikh
Suhail A Shaikh
ANAbhijit S. Naik
Abhijit S. Naik
LCLaura Cotiguala
Laura Cotiguala
KMKatie McMurry
Katie McMurry
JPJeong M. Park
Jeong M. Park
Despite the increased use, comparative safety and efficacy of direct‐acting oral anticoagulants (DOACs) against warfarin have not been well studied in kidney transplant recipients. In this single‐center retrospective study, we evaluated 197 adult kidney transplant recipients on DOAC or warfarin between January 1, 2011 to June 30, 2018. The primary outcome was incidence of major bleeding defined as a hemoglobin decrease ≥ 2 g/dl, blood transfusion ≥ 2 units, or symptomatic bleeding in a critical area or organ. Patients were initiated on anticoagulation therapy at a median of 6.5 years post‐transplant and followed for a median of 12.3 months. The rates of major bleeding were 7.2% per year with DOACs vs. 11.4% per year with warfarin (Mantel‐Cox p=0.15). No difference was found in composite bleeding, clinically relevant nonmajor bleeding, or thromboembolic events between the groups. There was a lower incidence of major bleeding with apixaban compared to all other anticoagulants (6.7% vs. 19.0%, p=0.027). After controlling for potential confounders, DOAC use was not associated with an increased risk of major bleeding (HR 0.73, 95% CI 0.27‐1.95). Further research is warranted to definitively determine whether DOACs are effective and safe alternatives to warfarin for anticoagulation in kidney transplant recipients.

16 December 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SVSarah E Vordenberg
Sarah E Vordenberg
JNJulianna Nichols
Julianna Nichols
VMVincent D Marshall
Vincent D Marshall
KWKristie Rebecca Weir
Kristie Rebecca Weir
MDMichael P Dorsch
Michael P Dorsch
Background: Given the public release of large language models, research is needed to explore whether older adults would be receptive to personalized medication advice given by artificial intelligence (AI) tools. Objective: This study aims to identify predictors of the likelihood of older adults stopping a medication and the influence of the source of the information. Methods: We conducted a web-based experimental survey in which US participants aged ≥65 years were asked to report their likelihood of stopping a medication based on the source of information using a 6-point Likert scale (scale anchors: 1=not at all likely; 6=extremely likely). In total, 3 medications were presented in a randomized order: aspirin (risk of bleeding), ranitidine (cancer-causing chemical), or simvastatin (lack of benefit with age). In total, 5 sources of information were presented: primary care provider (PCP), pharmacist, AI that connects with the electronic health record (EHR) and provides advice to the PCP (“EHR-PCP”), AI with EHR access that directly provides advice (“EHR-Direct”), and AI that asks questions to provide advice (“Questions-Direct”) directly. We calculated descriptive statistics to identify participants who were extremely likely (score 6) to stop the medication and used logistic regression to identify demographic predictors of being likely (scores 4-6) as opposed to unlikely (scores 1-3) to stop a medication. Results: Older adults (n=1245) reported being extremely likely to stop a medication based on a PCP’s recommendation (n=748, 60.1% [aspirin] to n=858, 68.9% [ranitidine]) compared to a pharmacist (n=227, 18.2% [simvastatin] to n=361, 29% [ranitidine]). They were infrequently extremely likely to stop a medication when recommended by AI (EHR-PCP: n=182, 14.6% [aspirin] to n=289, 23.2% [ranitidine]; EHR-Direct: n=118, 9.5% [simvastatin] to n=212, 17% [ranitidine]; Questions-Direct: n=121, 9.7% [aspirin] to n=204, 16.4% [ranitidine]). In adjusted analyses, characteristics that increased the likelihood of following an AI recommendation included being Black or African American as compared to White (Questions-Direct: odds ratio [OR] 1.28, 95% CI 1.06-1.54 to EHR-PCP: OR 1.42, 95% CI 1.17-1.73), having higher self-reported health (EHR-PCP: OR 1.09, 95% CI 1.01-1.18 to EHR-Direct: OR 1.13 95%, CI 1.05-1.23), having higher confidence in using an EHR (Questions-Direct: OR 1.36, 95% CI 1.16-1.58 to EHR-PCP: OR 1.55, 95% CI 1.33-1.80), and having higher confidence using apps (EHR-Direct: OR 1.38, 95% CI 1.18-1.62 to EHR-PCP: OR 1.49, 95% CI 1.27-1.74). Older adults with higher health literacy were less likely to stop a medication when recommended by AI (EHR-PCP: OR 0.81, 95% CI 0.75-0.88 to EHR-Direct: OR 0.85, 95% CI 0.78-0.92). Conclusions: Older adults have reservations about following an AI recommendation to stop a medication. However, individuals who are Black or African American, have higher self-reported health, or have higher confidence in using an EHR or apps may be receptive to AI-based medication recommendations.

11 February 2025 in JMIR Human Factors
Verified
Journal Article
Open access
JKJin Yong Kim
Jin Yong Kim
VMVincent D Marshall
Vincent D Marshall
BRBrigid Rowell
Brigid Rowell
QCQiyuan Chen
Qiyuan Chen
YZYifan Zheng
Yifan Zheng
XYXi Jessie Yang
Xi Jessie Yang
Background: Dispensing errors significantly contribute to adverse drug events, resulting in substantial health care costs and patient harm. Automated pill verification technologies have been developed to aid pharmacists with medication dispensing. However, pharmacists’ trust in such automated technologies remains unexplored. Objective: This study aims to investigate pharmacists’ trust in automated pill verification technology designed to support medication dispensing. Methods: Thirty licensed pharmacists in the United States performed a web-based simulated pill verification task to determine whether an image of a filled medication bottle matched a known reference image. Participants completed a block of 100 verification trials without any help, and another block of 100 trials with the help of an imperfect artificial intelligence (AI) aid recommending acceptance or rejection of a filled medication bottle. The experiment used a mixed subjects design. The between-subjects factor was the AI aid type, with or without an AI uncertainty plot. The within-subjects factor was the four potential verification outcomes: (1) the AI rejects the incorrect drug, (2) the AI rejects the correct drug, (3) the AI approves the incorrect drug, and (4) the AI approves the correct drug. Participants’ trust in the AI system was measured. Mixed model (generalized linear models) tests were conducted with 2-tailed t tests to compare the means between the 2 AI aid types for each verification outcome. Results: Participants had an average trust propensity score of 72 (SD 18.08) out of 100, indicating a positive attitude toward trusting automated technologies. The introduction of an uncertainty plot to the AI aid significantly enhanced pharmacists’ end trust (t28=–1.854; P=.04). Trust dynamics were influenced by AI aid type and verification outcome. Specifically, pharmacists using the AI aid with the uncertainty plot had a significantly larger trust increment when the AI approved the correct drug (t78.98=3.93; P<.001) and a significantly larger trust decrement when the AI approved the incorrect drug (t2939.72=–4.78; P<.001). Intriguingly, the absence of the uncertainty plot led to an increase in trust when the AI correctly rejected an incorrect drug, whereas the presence of the plot resulted in a decrease in trust under the same circumstances (t509.77=–3.96; P<.001). A pronounced “negativity bias” was observed, where the degree of trust reduction when the AI made an error exceeded the trust gain when the AI made a correct decision (z=–11.30; P<.001). Conclusions: To the best of our knowledge, this study is the first attempt to examine pharmacists’ trust in automated pill verification technology. Our findings reveal that pharmacists have a favorable disposition toward trusting automation. Moreover, providing uncertainty information about the AI’s recommendation significantly boosts pharmacists’ trust in AI aid, highlighting the importance of developing transparent AI systems within health care.

18 April 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
CLCorey Lester
Corey Lester
BRBrigid Rowell
Brigid Rowell
YZYifan Zheng
Yifan Zheng
ZCZoe Co
Zoe Co
VMVincent Marshall
Vincent Marshall
XYX Jessie Yang
X Jessie Yang
Background: Artificial intelligence (AI)–based clinical decision support systems are increasingly used in health care. Uncertainty-aware AI presents the model’s confidence in its decision alongside its prediction, whereas black-box AI only provides a prediction. Little is known about how this type of AI affects health care providers’ work performance and reaction time. Objective: This study aimed to determine the effects of black-box and uncertainty-aware AI advice on pharmacist decision-making and reaction time. Methods: Recruitment emails were sent to pharmacists through professional listservs describing a web-based, crossover, randomized controlled trial. Participants were randomized to the black-box AI or uncertainty-aware AI condition in a 1:1 manner. Participants completed 100 mock verification tasks with AI help and 100 without AI help. The order of no help and AI help was randomized. Participants were exposed to correct and incorrect prescription fills, where the correct decision was to “accept” or “reject,” respectively. AI help provided correct (79%) or incorrect (21%) advice. Reaction times, participant decisions, AI advice, and AI help type were recorded for each verification. Likelihood ratio tests compared means across the three categories of AI type for each level of AI correctness. Results: A total of 30 participants provided complete datasets. An equal number of participants were in each AI condition. Participants’ decision-making performance and reaction times differed across the 3 conditions. Accurate AI recommendations resulted in the rejection of the incorrect drug 96.1% and 91.8% of the time for uncertainty-aware AI and black-box AI respectively, compared with 81.2% without AI help. Correctly dispensed medications were accepted at rates of 99.2% with black-box help, 94.1% with uncertainty-aware AI help, and 94.6% without AI help. Uncertainty-aware AI protected against bad AI advice to approve an incorrectly filled medication compared with black-box AI (83.3% vs 76.7%). When the AI recommended rejecting a correctly filled medication, pharmacists without AI help had a higher rate of correctly accepting the medication (94.6%) compared with uncertainty-aware AI help (86.2%) and black-box AI help (81.2%). Uncertainty-aware AI resulted in shorter reaction times than black-box AI and no AI help except in the scenario where “AI rejects the correct drug.” Black-box AI did not lead to reduced reaction times compared with pharmacists acting alone. Conclusions: Pharmacists’ performance and reaction times varied by AI type and AI accuracy. Overall, uncertainty-aware AI resulted in faster decision-making and acted as a safeguard against bad AI advice to approve a misfilled medication. Conversely, black-box AI had the longest reaction times, and user performance degraded in the presence of bad AI advice. However, uncertainty-aware AI could result in unnecessary double-checks, but it is preferred over false negative advice, where patients receive the wrong medication. These results highlight the importance of well-designed AI that addresses users’ needs, enhances performance, and avoids overreliance on AI.